AI Article Synopsis
- Chiglitazar sodium is a new drug in China that targets multiple receptors (PPARα, PPARγ, and PPARδ) to help treat type 2 diabetes and improve metabolism.
- It works by enhancing insulin sensitivity, managing blood glucose levels, and increasing the breakdown and use of fatty acids.
- The drug is especially effective at a 48 mg dose for lowering both fasting and post-meal blood glucose levels in patients with high triglycerides.
Article Abstract
Chiglitazar sodium is a new peroxisome proliferator-activated receptor (PPAR) pan-agonist with independent intellectual property rights in China. It can treat type 2 diabetes mellitus and regulate metabolism by modestly activating PPARα, PPARγ, and PPARδ to improve insulin sensitivity, regulate blood glucose, and promote fatty acid oxidation and utilization. Chiglitazar sodium has a significant insulin-sensitizing effect and is advantageous in reducing fasting and postprandial blood glucose levels, particularly at the 48 mg dose in patients with concomitant high triglycerides in terms of blood glucose and triglyceride level control.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11596-023-2760-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!